Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.
Cornea. 2011 Oct;30(10):1110-4. doi: 10.1097/ICO.0b013e31821379aa.
To report on the safety and clinical use of combined subconjunctival and intracorneal bevacizumab for corneal neovascularization.
The charts of 12 consecutive patients with corneal neovascularization who received combined subconjunctival and intracorneal injections of bevacizumab (2.5 mg/0.1 mL) were reviewed. Patients received 1 to 3 injections of 2.5 mg of bevacizumab (1.25 mg/0.05 mL subconjunctival and 1.25 mg/0.05 mL intrastromal). Morphological changes were assessed clinically by 1 investigator.
Combined subconjunctival and intracorneal injections of bevacizumab were effective and well-tolerated. No significant ocular or systemic adverse events were observed during 6.4 months (range, 0.25-22 months) of follow-up. All patients showed a reduction in the neovascularized area.
Short-term results suggest that combined subconjunctival and intracorneal injections of bevacizumab are an effective method for reducing corneal neovascularization. It may be a useful option or adjunct to other treatments in stabilizing or improving vision.
报告联合应用球结膜下和角膜内注射贝伐单抗治疗角膜新生血管的安全性和临床应用。
回顾了 12 例连续角膜新生血管患者接受贝伐单抗（2.5mg/0.1ml）联合球结膜下和角膜内注射的病例。患者接受了 1 至 3 次 2.5mg 的贝伐单抗注射（1.25mg/0.05ml 球结膜下和 1.25mg/0.05ml 角膜内）。1 名研究者通过临床评估形态学变化。
联合应用球结膜下和角膜内注射贝伐单抗是有效且耐受良好的。在 6.4 个月（0.25-22 个月）的随访期间，未观察到明显的眼部或全身不良事件。所有患者的新生血管化区域均有减少。
短期结果表明，联合应用球结膜下和角膜内注射贝伐单抗是减少角膜新生血管的有效方法。它可能是稳定或改善视力的其他治疗方法的有效选择或辅助手段。
